Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 11/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517017 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4JAK2JAK1TYK2 | |
| SCHEMBL7098699 | 1.00 | ITGB1 (0.59) | ITGB1ITGA4JAK2JAK1TYK2 | |
| SCHEMBL7098046 | 0.94 | ITGB1 (0.51) | ITGB1ITGA4JAK2JAK1TYK2 | |
| SCHEMBL7098043 | 0.94 | ITGB1 (0.51) | ITGB1ITGA4JAK2JAK1TYK2 | |
| SCHEMBL7103726 | 0.91 | ITGB1 (0.49) | ITGB1ITGA4FPR2MEN1KMT2A | |
| SCHEMBL7103727 | 0.91 | ITGB1 (0.49) | ITGB1ITGA4FPR2MEN1KMT2A | |
| SCHEMBL7102565 | 0.90 | ITGB1 (0.48) | ITGB1ITGA4MEN1KMT2ANPSR1 | |
| SCHEMBL7102563 | 0.90 | ITGB1 (0.48) | ITGB1ITGA4MEN1KMT2ANPSR1 | |
| SCHEMBL7103673 | 0.88 | ITGB1 (0.59) | ITGB1ITGA4 | |
| SCHEMBL7104189 | 0.87 | ITGB1 (0.44) | ITGB1ITGA4MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ITGB1 3/4885ITGA4 8/4885JAK2 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.